albumin-bound docetaxel (CPO100) / CSPC Pharma - LARVOL DELTA

Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors (clinicaltrials.gov) - P2 | N=350 | Not yet recruiting | Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

New P2 trial • Esophageal Cancer • Gastric Cancer • Gastroesophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor

A Randomized, Controlled, Open-label Phase Ⅱ study of Becotatug (JMT101) Combined with Docetaxel (Albumin-Bound, HB1801) for Treatment of Patients (pts) with Locally Advanced/Recurrent or Distant Metastatic Squamous Cell Non-Small Cell Lung Cancer (sqNSCLC) (BATTLE study) [WITHDRAWN] (ELCC 2025) - No abstract available

Clinical • Metastases • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Efficacy and safety of albumin-bound docetaxel vs. docetaxel in patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma: A multicenter, randomized, phase II study. (ASCO-GI 2025) - P2 | " In this phase II study, eligible patients were aged 18-75 years with histologically confirmed gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, who progressed on at least first line of combined chemotherapy of platinum and fluorouracil. Compared with Taxotere, HB1801 results in 41% reduction in risk of death with a manageable safety profile in patients with previously treated advanced G/GEJ cancer."

Clinical • Metastases • P2 data • Esophageal Cancer • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor

A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer (clinicaltrials.gov) - P3 | N=630 | Recruiting | Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Enrolling by invitation ➔ Recruiting

Enrollment status • Gastric Cancer • Oncology • Solid Tumor

A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer (clinicaltrials.gov) - P3 | N=630 | Enrolling by invitation | Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Not yet recruiting ➔ Enrolling by invitation

Enrollment open • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

CPO-100-US-101: Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=126 | Active, not recruiting | Sponsor: Conjupro Biotherapeutics, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Metastases • Breast Cancer • Gastric Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Lung Cancer • Oncology • Ovarian Cancer • Prostate Cancer • Solid Tumor

A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel（Albumin Bound）Verse Docetaxel for the Treatment of MET-overexpressed Non-small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=256 | Not yet recruiting | Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Metastases • New P2 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A Study of Docetaxel for Injection (Albumin Bound) in Patients With Advanced Pancreatic Cancer (clinicaltrials.gov) - P3 | N=142 | Not yet recruiting | Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Metastases • New P3 trial • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor

Phase II randomized clinical trial comparing albumin-bound docetaxel vs. docetaxel in patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma. (ASCO 2024) - P2 | " In this phase II study, eligible patients were aged 18-75 years with histologically confirmed G/GEJ adenocarcinoma, who progressed on at least first line of combined chemotherapy of platinum and fluorouracil. These preliminary results suggest that HB1801 had manageable safety profile and promising efficacy in patients with previously treated advanced G/GEJ cancer. Clinical trial information: NCT05705635."

Clinical • Metastases • P2 data • Alopecia • Anemia • Esophageal Cancer • Fatigue • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Hematological Disorders • Immunology • Leukopenia • Oncology • Solid Tumor

Phase 1 study (NCT04931823) of CPO100 (albumin bound docetaxel) in patients with advanced solid tumors. (ASCO 2024) - P1 | "Preliminary data with CPO-100 administered on a weekly basis shows potential efficacy in heavily pretreated pts, especially with prior taxane exposure, with a tolerable WS. With a similar dose, CPO-100 demonstrated a better safety profile than docetaxel. The most prominent concern is manageable neutropenia, especially on a dose above 35 mg/m 2 , where GCSF supplementation was needed."

Clinical • Metastases • P1 data • Anemia • Dermatology • Fatigue • Head and Neck Cancer • Hematological Disorders • Hypotension • Immunology • Infectious Disease • Nasopharyngeal Carcinoma • Neutropenia • Oncology • Pain • Pneumonia • Respiratory Diseases • Solid Tumor

A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer (clinicaltrials.gov) - P3 | N=630 | Not yet recruiting | Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

New P3 trial • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma. (clinicaltrials.gov) - P1/2 | N=129 | Not yet recruiting | Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Combination therapy • IO biomarker • Metastases • Trial completion date • Trial initiation date • Trial primary completion date • Esophageal Cancer • Oncology • Squamous Cell Carcinoma • PD-L1

A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma. (clinicaltrials.gov) - P1/2 | N=129 | Not yet recruiting | Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Combination therapy • IO biomarker • Metastases • New P1/2 trial • Esophageal Cancer • Oncology • Squamous Cell Carcinoma • PD-L1

A Study to Compare the Efficacy and Safety of HB1801 to Taxotere in Advanced Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - P2 | N=80 | Recruiting | Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • EGFR • ROS1

The first patient was successfully enrolled! KN026 latest progress display [Google translation] (Beijing Huoshi Creation Data Technology) - "...CSPC and Jerry Corning...jointly announced that KN026 combined with HB1801 was compared with trastuzumab combined with pertuzumab and docetaxel in the first-line treatment of HER2-positive relapse The randomized, controlled, open, multi-center, phase III clinical study on the effectiveness and safety of subjects with metastatic breast cancer completed the first subject enrollment in the First People's Hospital of Yulin City, and the course of the subject's medication went smoothly. Observation after completion of administration."

Enrollment open • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

A Study to Compare the Efficacy and Safety of HB1801 to Taxotere in Advanced Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - P2 | N=80 | Not yet recruiting | Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Metastases • New P2 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • EGFR • ROS1

A Study of Docetaxel for Injection (Albumin-bound) in Patients With Pancreatic Cancer (clinicaltrials.gov) - P2 | N=53 | Recruiting | Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor

A Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer (clinicaltrials.gov) - P2 | N=100 | Recruiting | Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Metastases • New P2 trial • Esophageal Cancer • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor

A Study of Docetaxel for Injection (Albumin-bound) in Patients With Pancreatic Cancer (clinicaltrials.gov) - P2 | N=53 | Not yet recruiting | Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

New P2 trial • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor

A Study of Docetaxel for Injection (Albumin-bound) in Combination With Bevacizumab in Patients With Ovarian Cancer (clinicaltrials.gov) - P2 | N=94 | Recruiting | Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Not yet recruiting ➔ Recruiting | Initiation date: May 2022 ➔ Aug 2022

Combination therapy • Enrollment open • Trial initiation date • Oncology • Ovarian Cancer • Solid Tumor

A Study of Docetaxel for Injection (Albumin-bound) in Combination With Bevacizumab in Patients With Ovarian Cancer (clinicaltrials.gov) - P2 | N=94 | Not yet recruiting | Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Combination therapy • New P2 trial • Oncology • Ovarian Cancer • Solid Tumor

A Study of Docetaxel for Injection (Albumin-bound) in Combination With Nivolumab in Patients With Head and Neck (SCCHN) (clinicaltrials.gov) - P1/2 | N=94 | Recruiting | Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Not yet recruiting ➔ Recruiting | Initiation date: Nov 2021 ➔ Feb 2022

Combination therapy • Enrollment open • Trial initiation date • Gastrointestinal Cancer • Head and Neck Cancer • Oncology • Oropharyngeal Cancer • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • PD-L1

The Comparison of the Pharmacokinetics of Albumin-bound Docetaxel and Taxotere (clinicaltrials.gov) - P1 | N=27 | Active, not recruiting | Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Recruiting ➔ Active, not recruiting | Trial completion date: Feb 2022 ➔ Dec 2022 | Trial primary completion date: Nov 2021 ➔ Oct 2022

Enrollment closed • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

A Study to Evaluate the Safety and Efficacy of Docetaxel for Injection (Albumin-bound)in Different Dose Regimens in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1b | N=144 | Recruiting | Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Gastrointestinal Cancer • Oncology • Solid Tumor

Evaluation of the Safety and Efficacy of Albumin-bound Docetaxel (clinicaltrials.gov) - P1 | N=208 | Recruiting | Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Trial completion date: Jul 2023 ➔ Dec 2023 | Trial primary completion date: Mar 2022 ➔ Dec 2022

Trial completion date • Trial primary completion date • Oncology • Solid Tumor